Amneal Pharmaceuticals Reports Strong Q1 2025 Performance Amid Strategic Shift
Amneal Pharmaceuticals Inc. reports strong Q1 2025 performance, with 5% revenue growth and 50% EPS increase, driven by strategic initiatives and focus on high-growth therapeutic areas.
2 minutes to read